Potential therapeutic applications
“We provide new avenues by which to improve anticoagulant therapy by reducing the risk of bleeding”
Increased risk of life-threatening bleeding remains a major healthcare issue linked to the use of current anticoagulation drugs during procedures involving medical devices such as catheters, stents and extracorporeal circuits.
Bioxodes believes that, without increasing the incidence of major bleeds, Ir-CPI may be used in indications such as prevention of catheter occlusion, catheter-induced thrombosis and extracorporeal pump occlusion alongside systemic anticoagulation in such procedures as percutaneous coronary intervention (PCI) and cardiac artery bypass graft (CABG). Other potential indications include medical and/or upstream treatment of thromboembolic diseases such as myocardial infraction, pulmonary embolism and cerebral ischemia.